v3.26.1
Net financial results
 6 Months Ended
Jun. 30, 2026
Notes and other explanatory information [abstract]  
Disclosure of financial results
8 NET FINANCIAL RESULT
06/30/202606/30/2025
Financial expenses
Interest on loans, financing and debentures (1)

(2,832,258)
(2,733,269)
Premium expenses on early settlements (2)
(129,841)
Amortization of transaction costs

(84,591)
(48,174)
Interest expenses on lease liabilities (3)

(232,932)
(230,308)
Other

(231,290)
(234,773)
(3,510,912)
(3,246,524)
Financial income

Cash and cash equivalents and marketable securities

971,605 
702,662 
Other
38,162 
119,450 
1,009,767 
822,112 
Results from derivative financial instruments

Income

6,562,692 
7,015,340 
Expenses
(2,560,744)
(662,835)
4,001,948 
6,352,505 
Monetary and exchange rate variations, net

Exchange rate variations on loans, financing and debentures

3,615,919 
9,147,254 
Leases
138,600 
322,483 
Other assets and liabilities (4)
(649,306)
(1,276,652)
3,105,213 
8,193,085 
Net financial result
4,606,016 
12,121,178 
(1)Excludes R$44,289 arising from capitalized loan costs, substantially related to property, plant and equipment in progress of the Cerrado Project for the six-month period ended June 30, 2026 (R$126,119 as at June 30, 2025).
(2)R$121,752 related to the costs of early termination of the pre‑approved and undrawn credit facility with Finnvera.
(3)Includes R$119,255 eliminated resulting from the reclassification to the biological assets item for inclusion in the cost of formation (R$133,133 in the Consolidated as of June 30, 2025).
(4)Includes effects of exchange rate variations of trade accounts receivable, trade accounts payable, cash and cash equivalents, marketable securities and others.